BNP Paribas Financial Markets’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28M | Sell |
437,192
-210,539
| -33% | -$10.9M | 0.01% | 1066 |
|
|
2026
Q1 | $31.2M | Sell |
647,731
-184,046
| -22% | -$8.15M | 0.02% | 907 |
|
|
2025
Q4 | $34.3M | Buy |
831,777
+178,366
| +27% | +$7.16M | 0.02% | 877 |
|
|
2025
Q3 | $25.4M | Buy |
653,411
+227,464
| +53% | +$7.39M | 0.01% | 983 |
|
|
2025
Q2 | $11.8M | Buy |
425,947
+200,517
| +89% | +$5.1M | 0.01% | 1323 |
|
|
2025
Q1 | $5.01M | Buy |
225,430
+51,950
| +30% | +$1.07M | ﹤0.01% | 1812 |
|
|
2024
Q4 | $3.43M | Sell |
173,480
-19,446
| -10% | -$444K | ﹤0.01% | 2032 |
|
|
2024
Q3 | $4.82M | Buy |
192,926
+105,924
| +122% | +$2.58M | ﹤0.01% | 1524 |
|
|
2024
Q2 | $1.62M | Buy |
87,002
+40,942
| +89% | +$767K | ﹤0.01% | 2025 |
|
|
2024
Q1 | $909K | Sell |
46,060
-30,608
| -40% | -$598K | ﹤0.01% | 2555 |
|
|
2023
Q4 | $1.34M | Buy |
76,668
+7,846
| +11% | +$129K | ﹤0.01% | 2203 |
|
|
2023
Q3 | $1.2M | Sell |
68,822
-10,053
| -13% | -$169K | ﹤0.01% | 2217 |
|
|
2023
Q2 | $1.11M | Sell |
78,875
-47,671
| -38% | -$638K | ﹤0.01% | 2132 |
|
|
2023
Q1 | $1.36M | Buy |
126,546
+91,547
| +262% | +$1.21M | ﹤0.01% | 2111 |
|
|
2022
Q4 | $524K | Buy |
34,999
+24,207
| +224% | +$352K | ﹤0.01% | 2545 |
|
|
2022
Q3 | $139K | Sell |
10,792
-6,148
| -36% | -$70K | ﹤0.01% | 3643 |
|
|
2022
Q2 | $164K | Sell |
16,940
-44,257
| -72% | -$413K | ﹤0.01% | 3171 |
|
|
2022
Q1 | $608K | Buy |
61,197
+4,289
| +8% | +$45.4K | ﹤0.01% | 2643 |
|
|
2021
Q4 | $670K | Buy |
56,908
+51,275
| +910% | +$630K | ﹤0.01% | 2854 |
|
|
2021
Q3 | $64.2K | Buy |
5,633
+4,559
| +424% | +$59.4K | ﹤0.01% | 3444 |
|
|
2021
Q2 | $15K | Sell |
1,074
-2,425
| -69% | -$36.8K | ﹤0.01% | 3621 |
|
|
2021
Q1 | $64.8K | Buy |
3,499
+414
| +13% | +$8.47K | ﹤0.01% | 3524 |
|
|
2020
Q4 | $54.5K | Sell |
3,085
-3,305
| -52% | -$58.1K | ﹤0.01% | 3513 |
|
|
2020
Q3 | $97.9K | Buy |
6,390
+5,003
| +361% | +$93.9K | ﹤0.01% | 3128 |
|
|
2020
Q2 | $35.3K | Sell |
1,387
-3,139
| -69% | -$65.6K | ﹤0.01% | 3175 |
|
|
2020
Q1 | $70.1K | Buy |
4,526
+2,284
| +102% | +$35.7K | ﹤0.01% | 3386 |
|
|
2019
Q4 | $24.8K | Buy |
2,242
+26
| +1% | +$226 | ﹤0.01% | 3939 |
|
|
2019
Q3 | $18.9K | Buy |
2,216
+679
| +44% | +$7.5K | ﹤0.01% | 3973 |
|
|
2019
Q2 | $20.8K | Sell |
1,537
-1,148
| -43% | -$17.8K | ﹤0.01% | 3881 |
|
|
2019
Q1 | $48.5K | Buy |
2,685
+2,467
| +1,132% | +$47.7K | ﹤0.01% | 3507 |
|
|
2018
Q4 | $6.12K | Buy |
218
+80
| +58% | +$1.67K | ﹤0.01% | 3512 |
|
|
2018
Q3 | $3.52K | Buy |
+138
| New | +$2.68K | ﹤0.01% | 4167 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
SSC
BNP Paribas Financial Markets's KNSA Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its Kiniksa Pharmaceuticals (KNSA) stake by 33% in Q2 2026, selling an estimated $10.9M and leaving 437,192 shares worth $28M. The position accounts for 0.01% of the portfolio, ranked #1066.
BNP Paribas Financial Markets first reported a position in KNSA in Q3 2018 and has held it in 32 quarters since. The position peaked at $34.3M in Q4 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.
- BNP Paribas Financial Markets held 437,192 shares of Kiniksa Pharmaceuticals worth $28M as of Q2 2026.
- BNP Paribas Financial Markets sold 210,539 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $10.9M.
- Kiniksa Pharmaceuticals made up 0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #1066 holding.
- BNP Paribas Financial Markets first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- BNP Paribas Financial Markets's Kiniksa Pharmaceuticals position peaked at $34.3M in Q4 2025.
- 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.